Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Bendamustine (Primary) ; Ixazomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 07 Jun 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 06 Jun 2017 Results (As of Jan 2017, the phase I portion is complete (n= 15)) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology